Labcorp Declares $0.72 Quarterly Dividend, Payable March 12
Labcorp Holdings Inc. announced a quarterly cash dividend of $0.72 per share on January 14, 2026. The dividend will be paid to shareholders of record as of February 27.
Labcorp Holdings Inc. (NYSE: LH) declared a quarterly cash dividend of $0.72 per share, the company announced on January 14, 2026. The dividend will be paid on March 12 to shareholders of record at the close of business on February 27. Read more dividend announcements.
The diagnostic testing giant made the announcement alongside its fourth quarter 2025 financial results. The company did not disclose whether the dividend represents a change from the prior quarter.
| Dividend Details | Information |
|---|---|
| Amount | $0.72 per share |
| Record Date | February 27, 2026 |
| Payment Date | March 12, 2026 |
| Frequency | Quarterly |
Share Repurchase Activity
During the fourth quarter, Labcorp repurchased $225 million of common stock. For the full year 2025, the company returned $450 million to shareholders through share buybacks.
Fourth Quarter and Full Year 2025 Results
Labcorp reported total revenue of $3.52 billion for the fourth quarter ended December 31, 2025, up 5.6% from $3.33 billion in the prior year period. Organic revenue growth came in at 3.8% for the quarter.
For the full year 2025, total revenue reached $13.95 billion, a 7.2% increase from $13.01 billion in 2024. Organic revenue growth for the year was 4.4%.
Operating income for the fourth quarter was $267.6 million, or 7.6% of revenue, compared to $216.5 million, or 6.5% of revenue, in the prior year quarter. Full year operating income was $1.38 billion, or 9.9% of revenue, versus $1.09 billion, or 8.4% of revenue, in 2024.
Diluted earnings per share for the fourth quarter were $1.98, up from $1.70 in the prior year period. Full year diluted EPS reached $10.46, compared to $8.84 in 2024. On an adjusted basis, fourth quarter EPS was $4.07 versus $3.45, while full year adjusted EPS was $16.44 compared to $14.57.
Recent Business Developments
During the fourth quarter, Labcorp completed several strategic acquisitions, including select outreach laboratory services from Parkview Health, select outreach assets from Community Health Systems, and select anatomic pathology assets from Incyte Diagnostics. After the quarter ended, the company completed the acquisition of select assets of Empire City Laboratories.
The company launched the first FDA-cleared blood test for Alzheimer's disease assessment in primary care settings during the quarter. It also expanded access to molecular residual disease testing for certain stages of breast, lung and colon cancer.
Labcorp announced it became the first U.S. commercial laboratory to enter an agreement to implement Roche's fully automated mass spectrometry solution. The company also disclosed plans for a strategic investment to build a new 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026.